Boehringer Ingelheim returned to reinvest in the in-vitro diagnostics technology company, taking its overall funding to more than $50m as it gears up to release its product.
Spain-based medical diagnostics technology developer Stat-Diagnostica has completed a €25m ($28.5m) series C round featuring Boehringer Ingelheim Venture Fund, pharmaceutical company Boehringer Ingelheim’s corporate venturing unit.
Venture capital firm Gilde Healthcare led the round, which included Caixa Capital Risc, the venture capital arm of financial services firm La Caixa, and Spanish state-owned fund manager Axis, as well as Kurma Partners, Ysios Capital and Idinvest Partners.
Founded in 2010, Stat-Diagnostica has built an in-vitro diagnostic system called DiagCore that combines molecular…
